HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $1.5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen maintains a Neutral rating on Co-Diagnostics (NASDAQ:CODX) and lowers the price target from $2 to $1.5.
August 12, 2024 | 6:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HC Wainwright & Co. analyst Yi Chen maintains a Neutral rating on Co-Diagnostics and lowers the price target from $2 to $1.5.
The lowered price target from $2 to $1.5 by HC Wainwright & Co. suggests a negative outlook on Co-Diagnostics' stock performance, likely leading to a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100